[Corrigendum] METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma

Li,Min; Xia,Mingyue; Zhang,Ziyu; Tan,Yanyin; Li,Enjie; Guo,Zhigang; Fang,Mingzhi; Zhu,Yong; Hu,Zhigang

doi:10.3892/ijo.2023.5549

September-2023 Volume 63 Issue 3

Full Size Image

Cover Legend PDF

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2023 Volume 63 Issue 3

Full Size Image

Cover Legend PDF

Correction Open Access

[Corrigendum] METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma

Authors:
- Min Li
- Mingyue Xia
- Ziyu Zhang
- Yanyin Tan
- Enjie Li
- Zhigang Guo
- Mingzhi Fang
- Yong Zhu
- Zhigang Hu
View Affiliations / Copyright

Affiliations: Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China, Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu 210023, P.R. China, National Centre of Colorectal Disease, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 101
|
Published online on: July 24, 2023

https://doi.org/10.3892/ijo.2023.5549
Expand metrics +

Article

Int J Oncol 61: [Related article:] 106, 2022; DOI: 10.3892/ijo.2022.5396

Subsequently to the publication of the above article, the authors alerted us to the fact that the data shown in Fig. 8I (for the 'Sh-CN / 0' panel) on p. 11 were mistakenly selected from those data belonging to the experiments shown in Fig. 7H (the 'Sh-CN / 0' panel) of this paper during the final assembly of the figures for review. Note that this error did not affect the conclusions reported in this paper, as both Fig. 7H ('Sh-CN / 0') and Fig. 8I ('Sh-CN / 0') show negative controls of the Comet assay, with no obvious trailing.

Figure 8

Inhibition of RAD51AP1 overcomes 5-FU-resistance in colorectal cancer cells. (A) Western blot analysis of RAD51AP1 in control and RAD51AP1-KD HCT-8R cells. (B) Cell survival assay in control and RAD51AP1-KD HCT-8R cells. (C) Morphological analysis of control and RAD51AP1-KD HCT-8R cells with 60 µg/ml 5-FU treatment for 48 h. (D) Knockdown of RAD51AP1 promotes apoptosis in HCT-8R cells with 5-FU treatment. (E) Silencing of RAD51AP1 induces caspase-3 and Bax expression in HCT-8R cells following 5-FU treatment. (F) Western blotting to determine γ-H2AX levels in control and RAD51AP1-KD HCT-8R cells following 5-FU treatments for 4 h. (G and H) Immunofluorescence staining of γ-H2AX foci and 53BP1 foci in different cells treated 5-FU for 4 h. (I) Comet assay of RAD51AP1-KD and control HCT-8R cells treated with or without 5-FU (60 µg/ml) for 12 h. *P<0.05, **P<0.01 and ***P<0.001. RAD51AP1, RAD51 associated Protein 1; 5-FU, 5-fluorouracil; KD, knockdown; HCT-8R, 5-FU-resistant HCT-8 cells; sh-, small hairpin; CN, control.

The revised version of Fig. 8, showing the correct data for the 'Sh-CN / 0' panel in Fig. 8I, is shown on the next page. The authors are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum, and all the authors agree with its publication. Furthermore, the authors apologize to the readership for any inconvenience caused.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma

This article is mentioned in:

Article

Figure 8

Related Articles